The propaganda launched by the multinational drug companies aiming at tarnishing image of the pharmaceutical industries of developing countries had already done enough damage to the Indian pharma sector. MNC lobby has been able to successfully misguide the government agencies of the US and European nations into believing that most of fake and spurious drugs are being made in India and China. Some of the UN organizations have also given a supporting hand to the MNCs in this regard. Such sustained campaigns have already affected India's pharmaceutical exports to the US, Europe, Latin America and Africa since last year. India's top companies like Ranbaxy, Dr. Reddy's, Sun Pharma, Wockhardt and others are now struggling to keep their images in these overseas markets. It is quite unfortunate that such repeated and false propaganda of MNCs in visual and print media has started even influencing the organizations and government agencies within India. What is happening in Mizoram is nothing but a fall out of this vicious campaign. The state government of Mizoram has made it mandatory for all drug companies operating in India to register all their medicines entering into the state from September 1. The state government has also decided to impose a fee of Rs 50 per product. The stated objective of the Mizoram government is to curb the entry of spurious drugs into the state. The state government concern to protect its public from adverse effects of fake and spurious drugs is understandable. But what is overlooked by the chief minister of Mizoram is that all drugs manufactured and marketed in the country are as per the provisions of Drugs & Cosmetics Act. Once a pharmaceutical product is approved for manufacturing and marketing by any state drug administration in the country, it can be marketed all states and Union territories in the country. There cant be any state wise restriction on such sales. To impose any kind of marketing restriction on such legitimately approved products is an unconstitutional act and can be easily challenged in any court of law. It is a different matter that nobody attempted it so far. The Mizoram action also questions the fundamental right of the manufacturers and traders of pharmaceutical products in other parts of the country. When they are free to sell their products all over the country why a restriction only in one state. The Centre has to immediately intervene in this matter and bring status quo to avoid spread of such unwarranted action to other parts of the country. It is possible that some other states especially the north eastern states may resort to this kind of tactics just as a new way of revenue raising option.